Skip to main content
Erschienen in: Journal of Cardiothoracic Surgery 1/2020

Open Access 01.12.2020 | Research article

Lymph node metastatic patterns and its clinical significance for thoracic superficial esophageal squamous cell carcinoma

verfasst von: An Wang, Lu Lu, Jie Fan, Shaohua Wang, Xiaofeng Chen

Erschienen in: Journal of Cardiothoracic Surgery | Ausgabe 1/2020

Abstract

Background and objectives

The optimal therapeutic method for patients with superficial esophageal squamous cell carcinoma (sESCC) remains to be established.

Methods

Clinical data of all the patients from 2002 to 2014 who underwent curative esophagectomy and three-field lymphadenectomy for thoracic sESCC were collected based on a prospectively-maintained database. The pattern of lymph node metastasis was analyzed based on the depth of tumor invasion, tumor location and surgical fields.

Results

The involved lymph node region was associated to the tumor location, however, upper mediastinal and perigastric region was the most vulnerable region. The incidence of lymph node metastasis increased with the depth of tumor invasion. No lymph node involvement was found in tumors invading proper mucosa (M2), while the pattern of positive lymph nodes in tumors invading the deepest 1/3 submucosa was similar to that in advanced ESCC. Lymphatic invasion, tumor location and upper mediastinal lymph node involvement were independent predictors for cervical lymph node metastasis. For patients without lymphatic invasion, the positive predictive value of upper mediastinal lymph node metastasis for positive cervical lymph node was low (0 ~ 25%), while the negative predictive value was extremely high, wherever the tumor located (93.8 ~ 100%).

Conclusions

Tumors invading till proper mucosa was the best indication for endoscopic mucosa resection. Mediastinal-abdominal lymphadenectomy was essential for sESCC invading beyond proper mucosa. For those without lymphatic invasion, cervical lymphadenectomy might be avoided in case of negative upper mediastinal lymph node.
Hinweise
An Wang and Lu Lu contributed equally to this work. They are co-first authors. Shaohua Wang and Xiaofeng Chen contributed equally to this work. They are co-corresponding authors.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
sESCC
Superficial esophageal squamous cell carcinoma
H.E
Haematoxylin and eosin
EMR
Endoscopic mucosal resection
ESD
Endoscopic submucosal dissection
SLNB
Sentinel lymph node biopsy

Introduction

With the advent and development of multimodality therapy, many patients with superficial esophageal squamous cell carcinoma(sESCC) can benefit from endoscopic mucosa resection for its low possibility of lymph node metastasis [1]. As the most significant prognostic factor for esophageal squamous cell carcinoma [2], the status of lymph node metastasis is the basis for therapy choice. However, currently there is no reliable pre-excision molecular, biological or immunohistochemical predictive markers of lymph node metastasis in superficial esophageal cancer, and the diagnostic performance of preoperative workup for nodal disease is poor [3]. There are literatures [46] which demonstrated the prevalence and characteristics of lymph node involvement in superficial esophageal cancer, however the significance of the results is limited because of the heterogeneity in histological type and surgical methods. Herein we summarized the patterns of lymph node metastasis assessed by three-field lymphadenectomy in sESCC in our institute with a period of 12 year, aiming to investigate the best therapeutic recommendations for sESCC.

Methods

Patient enrollment

We conducted computerized and manual searches with the keyword ‘T category = 1’, ‘right transthoracic surgical procedure’, ‘R0 resection’ and ‘histology type = ESCC’ in our prospectively-maintained database; the patients who had received preoperative chemotherapy or radiotherapy were excluded (Fig. 1). At last, there remained 228 patients, who received esophagectomy and cervical-mediastinal-abdominal lymphadenectomy with curative intention for thoracic sESCC from the beginning of 2002 to the end of 2014.

Evaluation of tumor invasive depth

Recently, the pathological subclassication of the extent of the cancerous invasion in supercial esophageal cancer has been commonly utilized [Endo, Leers]. Depth of tumor invasion was classified as mucocal (m) and submucosal(sm) based on whether there was tumor invasion through the deepest muscular fibers of the muscularis mucosa. Both mucosal cancer and submucosal cancer were each further divided into three subtypes according to the extent of invasion, i.e. m1, m2, m3 cancers and sm1, sm2, sm3 cancers. Cases of m1 cancer included epithelial cancer, including cases in which it was questionable whether or not there was invasion to the lamina propria mucosae. Cancer invasive to the lamina propria mucosae was classied as m2, and m3 cancer cases included cases with invasion in contact with or into the muscularis mucosae. Submucosal cancers were also divided into three subtypes: sm1 cancer consisted of cases with invasion within the upper third layer of the submucosa, invasion to the middle third layer of the submucosa was classified as sm2 and invasion as far as the lower third layer of the submucosa was classified as sm3.
Representative slices of H.E. staining were re-evaluated by two pathologists (a deputy chief physician and an attending physician), who were blinded to surgical oncological results. They made independent assessment on tumor invasive depth using the new naming subclassification system described above. Disagreements were resolved through consensus on a multi-head microscope.

Data collection

All patient data, including demographic characteristics, tumor location, tumor differentiation, pathological T category, pathological N category, pathological M category, pathological TNM stage and adjuvant therapeutic regime were collected from our prospectively-maintained database. Staging was judged pathologically using the 7th edition of the UICC TNM classification system.

Surgical procedure for esophagectomy and 3-field lymphadenectomy

The standard surgical procedure used in our study was a combination of esophagectomy with mediastinal lymphadenectomy via right thoracotomy, upper abdominal lymphadenectomy, reconstruction with a gastric tube via the posterior mediastinum, and anastomosis in the cervical incision. 3-FL lymphadenectomy was adopted for all patients. We removed the left recurrent laryngeal nerve lymph nodes from the right thoracic cavity. Cervical lymph nodes contained both sides of the supraclavicular lymph nodes, middle deep cervical lymph nodes and cervical paraesophageal lymph nodes in 3-FL lymphadenectomy.

Areas of lymph node metastasis

The lymph node metastatic pattern of sESCC was investigated according to the tumor location and tumor invasive depth. The lymph node areas were divided as follows: (1), cervical lymph nodes; (2), upper mediastinal area including paratracheal nodes, nodes along both recurrent laryngeal nerves and upper paraesophageal nodes; (3), mid-mediastinal area including middle paraesophageal nodes and subcarinal nodes; (4), lower mediastinal area from the caudal margin of the inferior pulmonary vein including lower paraesophageal nodes and diaphragmatic nodes; and (5),abdominal area including paragastric nodes, common hepatic nodes, splenic nodes, and celiac nodes.

Evaluation of lymphovascular invasion

In the present study, lymphovascular invasion was defined as lymphatic and (or) vascular invasion. The method to evaluate and distinguish lymphatic invasion from vascular invasion was described in our previous study [7]. Briefly, the presence of erythrocytes within the involved vessel lumen and the relatively large diameter of the involved vessel helped to distinguish vascular invasion from lymphatic invasion. For difficult cases or those cases without definitively positive evidence of lymphovascular invasion by haematoxylin and eosin (HE) staining, CD34 staining, which detects vascular endothelium, and podoplanin staining, which detects lymphatic endothelium were applied in representative slices for better detection and distinction. The evaluation of lymphovascular invasion was independently performed by two experienced pathologists, both of whom were blinded to the surgical oncological information. Disagreements were discussed and resolved through consensus.

Statistics analysis

Statistics analysis was conducted using the SPSS 19.0 Statistics Software Package (SPSS Inc., Chicago, IL). Unless stated otherwise, mean values and standard deviations are reported. Student’s t-test was used for comparisons between subgroups. For categorical variables, the χ2 test or Fisher’s exact test was used as appropriate. For identifying risk factors, those variables with a p value less than 0.1 according to univariate analysis were then included into a binary logistics regression analysis using the backward wald stepwise method. For all statistical analyses, p values less than 0.05 were considered significant.

Results

Demographics and clinicopathologic characteristics of all patients

The demographics and clinicopathological characteristics were listed in Table 1. The surgical mortality was 3/228 (1.3%). The median of removed regional lymph node was 34 (8–70). The median of removed lymph node in cervical, thoracic and abdominal area was 18, 20 and 13 respectively.
Table 1
Demographics and clinicopathologic characteristics
Variables
N(%)
Gender
 Male (%)
202 (88.6)
 Female (%)
26 (11.4)
Age (y)
median:64, min-max:41–82
Tumor location
 Upper Tx (%)
34 (14.9)
 Mid Tx (%)
125 (54.8)
 Lower Tx (%)
69 (30.3)
Macroscopic tumor type
 0-I
70 (30.7)
 0-IIa
45 (19.7)
 0-IIb
3 (1.3)
 0-IIc
103 (45.2)
 0-III
7 (3.1)
Tumor length(mm)
median:36, min-max:2–180
Differentiation
 Well (%)
58 (25.4)
 Moderate (%)
86 (37.7)
 Poor (%)
84 (36.8)
Growth pattern
 Expansive (%)
82 (36.0)
 Infiltrative (%)
146 (64.0)
Lymphatic invasion
 Absent (%)
166 (72.8)
 Present (%)
62 (27.2)
Vascular invasion
 Absent (%)
189 (82.9)
 Present (%)
39 (17.1)
pT category
 T1a (%)
62 (27.2)
 M2
27
 M3
35
 T1b (%)
166 (72.8)
 SM1
57
 SM2
61
 SM3
48
pN category
 N0 (%)
135 (59.2)
 N1 (%)
69 (30.3)
 N2 (%)
19 (8.3)
 N3 (%)
5 (2.2)
pM category
 M0 (%)
212 (93.0)
 M1 (lym) (%)
16 (7.0)
pStage
 Stage I(%)
133 (58.3)
 Stage II(%)
64 (28.1)
 Stage III(%)
15 (6.6)
 Stage IV (lym)(%)
16 (7.0)
Tx thorax, NS no significance

Prevalence of lymph node metastasis in different areas according to tumor location and depth of tumor invasion

None of the cases with tumor invading mucosa proper lamina (m2) had lymph node metastasis. Generally speaking, the most susceptible lymph nodes were in upper mediastinal area (48/228, 21.1%) and abdominal perigastric area (47/228, 20.6%). Tumors located at upper thoracic esophagus were most likely to have lymph node metastasis at upper mediastinal (15/34, 44.1%) and cervical area (8/34, 23.5%), while it was uncommon for tumors located at lower thoracic esophagus to develop lymph node metastasis at upper mediastinal area (4/69, 5.8%). Few patients with tumor located at lower thoracic esophagus had cervical lymph nodes metastasis (1/69, 1.4%). For tumors invading the deepest 1/3 layer of submucosa, the prevalence of lymph node metastasis in the upper mediastinal area and perigastric area was about 40%. The prevalence of lymph node metastasis increased with the depth of tumor. No matter which layer of submucosal was involved, the most common involved area was upper mediastinum and abdominal perigastric area (Table 2).
Table 2
Primary tumor location, tumor invasion depth and areas of nodal metastasis
 
Total
Tumor location
Tumor invasive depth
N = 228 (%)
Upper (n = 34)(%)
Mid (n = 125)(%)
Lower (n = 69)(%)
P value
M3 (n = 35)(%)
SM1 (n = 57)(%)
SM2 (n = 61)(%)
SM3 (n = 48)(%)
P value
Cervical
23 (10.1)
8 (23.5)
14 (11.2)
1 (1.4)
0.002
2 (5.7)
3 (5.3)
6 (9.8)
12 (25.0)
0.002
Upper mediastinum
48 (21.1)
15 (44.1)
29 (23.2)
4 (5.8)
<  0.001
1 (2.9)
12 (21.1)
16 (26.2)
19 (39.6)
<  0.001
Mid-mediastinum
12 (5.3)
2 (5.9)
8 (6.4)
2 (2.9)
NS
1 (2.9)
2 (3.5)
1 (1.6)
8 (16.7)
0.003
Lower mediastinum
21 (9.2)
2 (5.9)
12 (9.6)
7 (10.1)
NS
2 (5.7)
5 (8.8)
4 (6.6)
10 (20.8)
0.02
Perigastric
47 (20.6)
2 (5.9)
26 (20.8)
19 (27.5)
0.038
3 (8.6)
10 (17.5)
14 (23.0)
20 (41.7)
<  0.001

Operative fields distribution of metastatic lymph nodes according to tumor location

Tumors located at lower thoracic segment (Table 3) never had separate cervical lymph node metastasis while cervical lymph node metastasis occurred in patients with simultaneous thoracic and abdominal lymph node involvement. Few patients whose tumors were at upper thoracic esophagus had abdominal lymph node metastasis, among whom there was 1 patient with separate abdominal lymph node metastasis. Tumors at middle thoracic esophagus tended to spread cephalicly and caudally to all the three operative fields (Table 3).
Table 3
Lymph node metastatic characteristics according to operative fields in positive node disease
Number of cases with nodal disease according to operative field (%)
Tumor Location
Upper Tx
N = 19
Middle Tx
N = 52
Lower Tx
N = 25
1-field
 Cervical
2 (10.5)
2 (3.8)
0
 Thoracic
10 (52.6)
19 (36.5)
6 (24.0)
 Abdominal
1 (5.3)
9 (17.3)
15 (60.0)
2-field
 Cervical-Thoracic
5 (26.3)
5 (9.6)
0
 Thoracic-Abdominal
0
10 (19.2)
3 (12.0)
 Cervical-Abdominal
1 (5.3)
3 (5.8)
0
3-field
 Cervical-Thoracic-Abdominal
0
4 (7.6)
1 (4.0)
Tx thoracic

Analysis of correlated factors for cervical lymph node metastasis

Univariate analysis (Table 4) showed that age (< 65y) (p = 0.086), tumor location (p = 0.002), lymphatic invasion (p <  0.001), depth of tumor invasion (p = 0.002), and positive lymph node involvement in other area (upper mediastinal area, p <  0.001; middle mediastinal area, p = 0.003; lower mediastinal area, p = 0.011; abdominal perigastric area, p = 0.029) were potentially correlated with cervical lymph node metastasis. Multivariate analysis (Table 4), the efficacy of which was demonstrated by a Chi-square test (p <  0.001) demonstrated that tumor location (p = 0.006), lymphatic invasion (p = 0.001), and upper mediastinal lymph node metastasis (p = 0.03) were independent correlated factors with cervical lymph node involvement.
Table 4
Univariate and multivariate analysis of predictors for cervical lymph node metastasis in superficial thoracic ESCC
Variables
Univariate analysis
Multivariate analysis
Cervical LN(−)(%)
Cervical LN(+) (%)
P value
HR
95% CI for HR
P value
Age
  
0.086
0.283
  < 65 y
104 (86.7)
16 (13.3)
    
  ≥ 65 y
10 (93.5)
7 (6.5)
    
Gender
  
0.911
 Male
180 (89.1)
22 (10.9)
    
 Female
25 (96.2)
1 (3.8)
    
Tumor location
  
0.002
0.304
0.130–0.711
0.006
 Upper thorax
26 (76.5)
8 (23.5)
    
 Middle thorax
111 (88.8)
14 (11.2)
    
 Lower thorax
68 (98.6)
1 (1.4)
    
Tumor size
  
0.888
  ≤ 4 cm
119 (90.2)
13 (9.8)
    
  > 4 cm
86 (89.6)
10 (10.4)
    
Macroscopic tumor type
  
0.914
 0-II
136 (90.1)
15 (9.9)
    
 0-I/0-III
69 (89.6)
8 (10.4)
    
Tumor differentiation
  
0.128
Well differentiation
53 (91.4)
5 (8.6)
    
Moderate differentiation
73 (84.9)
13 (15.1)
    
Poor differentiation
79 (94.0)
5 (6.0)
    
Growth pattern
  
0.134
 Expansive
77 (93.9)
5 (6.1)
    
 Infiltrative
128 (87.7)
18 (12.3)
    
Lymphatic invasion
  
<  0.001
6.454
2.202–18.919
0.001
Absence
159 (95.8)
7 (4.2)
    
Presence
46 (74.2)
16 (25.8)
    
Vascular invasion
  
0.560
 
Absence
171 (90.5)
18 (9.5)
    
Presence
34 (87.2)
5 (12.8)
    
Pathological T category
  
0.002
 
T1a (%)
 M2
27 (100)
0
    
 M3
33 (94.3)
2 (5.7)
    
T1b (%)
 SM1
54 (94.7)
3 (5.3)
    
 SM2
55 (90.2)
6 (9.8)
    
 SM3
36 (75.0)
12 (25.0)
    
Upper mediastinal LN metastasis
  
<  0.001
3.196
1.118–9.136
0.03
Absence
171 (95.0)
9 (5.0)
    
Presence
34 (70.8)
5 (29.2)
    
Mid mediastinal LN metastasis
  
0.003
   
Absence
198 (91.7)
18 (8.3)
    
Presence
7 (58.3)
5 (41.7)
    
Lower mediastinal LN metastasis
  
0.011
   
Absence
190 (91.8)
17 (8.2)
    
Presence
15 (71.4)
6 (28.6)
    
Abdominal mediastinal LN metastasis
  
0.029
   
Absence
167 (92.3)
14 (7.7)
    
Presence
38 (80.9)
9 (19.1)
    
LN lymph node, CI confidence interval, HR hazard ratio, ESCC esophageal squamous cell carcinoma

Predictive value of the status of upper mediastinal lymph nodes for the status of cervical lymph nodes

Patients were stratified by the status of lymphatic invasion and tumor location (Table 5). For patients with negative lymphatic invasion, the positive predictive value of upper mediastinal lymph node metastasis for positive cervical lymph node was low (0 ~ 25%, depending on the tumor location), while the negative predictive value was extremely high, wherever the tumor located (93.8 ~ 100%). For patients with positive lymphatic invasion, the positive predictive value increased to 42.9 ~ 61.5% for tumors located at upper or middle thoracic esophagus, while the negative predictive value decreased to 33.3% for upper thoracic sESCC. For middle or lower thoracic sECSS, the negative predictive value was decreased but was still high (88.9 ~ 94.1%).
Table 5
Analysis of relationship between the status of upper mediastinal lymph nodes and the status of cervical lymph nodes
Lymphatic invasion
Tumor location
Upper mediastinal LN
Cervical LN-
Cervical LN
Positive predictive value (%)
Negative predictive value (%)
Auucracy (%)
+
Upper Tx
15
1
25.0
93.8
70.8
+
6
2
Mid Tx
75
3
6.25
96.2
80.9
+
15
1
Lower Tx
48
0
0
100
100
+
0
0
+
Upper Tx
1
2
42.9
33.3
40.0
+
4
3
Mid Tx
16
2
61.5
88.9
77.4
+
5
8
Lower Tx
16
1
0
94.1
76.2
+
4
0
LN lymph node, Tx: Thorax

Discussion

Our study sought to summarize the characteristics of lymph node metastasis in thoracic T1 sESCC. We found that patients with their tumor invading the layer of proper mucosal (M2) never had lymph node metastasis. The prevalence of lymph node involvement increased with the depth of tumor invasion. Upper mediastinal and (or) abdominal perigastric lymph nodes were most likely involved nodes wherever the tumor was located and whichever layer of submucosa the tumor invaded. Tumors located at lower thoracic segment never had separate cervical lymph node metastasis. The tumor location, lymphatic invasion, and upper mediastinal lymph node metastasis were independent correlated factors with cervical lymph node involvement. The negative predictive value of upper mediastinal lymph node involvement for cervical lymph node metastasis was high for middle and especially lower thoracic sESCC regardless of the status of lymphatic invasion.
Esophagectomy plus lymph node dissection remains the standard treatment especially in more advanced cases. However, there is controversy between surgeons and endoscopists as to which is the optimal option for those tumors invading M2, M3 or SM1. Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) are increasingly used to treat superficial esophageal cancer. Such endoscopic procedure could have achieved good survival outcomes had the lymph nodes not been involved. Our results showed that none of the patients with M2 tumor had lymph node metastasis, which was consistent with the literatures [810]. These results supported the role of endoscopic procedure as a radical therapy for M2 lesion. Eguchi and colleagues [11] concluded that M1 and M2 lesions were the best candidates for EMR although they demonstrated that the rate of lymph node metastasis in M2 lesion was 5.6%. Eguchi and colleagues [11] showed the lymph node metastatic rate for M3 cancer without lymphatic invasion, M3 cancer with lymphatic invasion, SM1 cancer and SM2/3 cancer was 10.3, 41.7, 53.1 and 53.9% respectively. Araki and his colleagues [3] reported the lymph node metastatic rate for SM1-SM3 was 12.2, 18.4 and 28.6% respectively. A much higher metastatic rate of 24.0, 20.5, 43.8% for SM1, SM2, and SM3 was reported by Li and his colleagues [5]. From the perspective of lymph node metastasis, endoscopic treatment is not suitable for submucosa esophageal cancer. Generally speaking, absolute indication for EMR was restricted to M1 or M2 cancers [12], which is consistent to our results in Table 2.
The incidence of lymph node metastasis and number of positive lymph node increased from SM1 to SM2 to SM3 [3, 13, 14]. According to the literature, the rate of lymph node metastasis in SM3 patients ranged from 25 to 75%, which is similar to progressive esophageal cancer [3, 5, 15, 16]. Surgery is necessary to SM3 patients. Esophagectomy with lymphadenectomy should be adopted for SM2 or SM3 patients. Li and his colleagues [5] reported only one SM3 patient with tumor located at upper third thoracic segment esophagus developed cervical nodal metastases among 20 submucosal patients who underwent three-field lymphadenectomy. In our study, only one patient with lower thoracic tumor had neck lymph node metastasis and the separate neck lymph node metastasis was rare in middle and lower esophageal cancer. Given the low prevalence of cervical metastasis and the high hospital morbidity after 3-field lymphadenectomy, can we avoid the neck surgical incision in selected patients? In our study, tumor location (p = 0.006), lymphatic invasion (p = 0.001), and upper mediastinal lymph node metastasis (p = 0.03) were independent correlated factors with cervical lymph node involvement while no association was found between cervical lymph node metastasis and T stage. This may be attributed to the facts that the subgroups of superficial esophageal cancer were too detailed. Tumor location (p = 0.006) is the most significant predictive factor regardless of stage. Tumors located at lower thorax never had separate cervical lymph node metastasis. So the cervical lymph node lymphadenectomy may be unnecessary for these patients if no lymph node metastasis were identified in upper mediastinal lymph node. Lymphatic invasion (p = 0.001) is another significant factor for predicting cervical lymph node metastasis. In recent years superficial esophageal cancers with increasing number are removed through endoscopic procedures. The status of lymphatic invasion could be demonstrated through the pathological examination of endoscopicly removed specimen. Therefore, lymphatic invasion is of particular significance in today’s clinical practice.
Sentinel lymph node biopsy (SLNB) was an effective method to detect lymph node metastasis and save surgery time and hospital cost in superficial esophageal cancer [17, 18]. The detection rate and accuracy has been validated by a meta-analysis in early esophageal cancer [19]. However, some disadvantages of SLNB could not be ignored. First, the procedures of SLNB is invasive, which may increase the patient’s preoperative trauma [17]. Moreover, many of the chest lymph nodes are black, which is difficult to distinguish from dyeing agent. The rapid transit of blue dye through lymphatic chain limits its use during the operation time [20]. The prognosis will be poor in patients with negative sentinel lymph node and positive non-sentinel lymph node [17]. In our study, the positive predictive value of upper mediastinal lymph node metastasis was not satisfactory no matter in low-risk or in high-risk patients. However, the negative predictive value was not low, especially for low-risk patients without lymphatic invasion, the negative predictive value of upper mediastinal lymph node metastasis for cervical lymph node metastasis was extremely high (93.8–100%). Even in high-risk patients with lymphatic invasion, the negative predictive value of upper mediastinal lymph node metastasis for cervical lymph node metastasis was also relative high (88.9–84.1%) in middle and lower thoracic tumors patients. This means cervical lymphadenectomy could be avoided for low-risk patients with negative upper mediastinal lymph nodes, particularly for patients with lower thoracic tumors. So, the lymph node metastasis in upper mediastinum can be used as “negativity sentinel lymph node” for negative cervical lymph nodes.
In our study, we excluded patients receiving neoadjuvant therapy, which make it difficult to assess lymphatic invasion. Due to constraints of time and resources, we only made qualitative analyses on lymphatic invasion in the current study. Moreover, this was a retrospective study for superficial ESCC from a single institute, the selective bias and heterogeneity of the patients could not be ignored— the conclusion of our research should be applied with caution. Additionally, the optimal therapeutic method was discussed based on the status of lymph nodes from a surgeon’s point of view. Further clinical trials regarding the prognosis are necessary to establish the best treatment for superficial ESCC.

Conclusions

In conclusion, tumors invading till proper mucosa were the best indication of EMR. For those without lymphatic invasion, it could be reasonable to avoid cervical lymphadenectomy, if nodes of the upper mediastinum resulted negative at the frozen section, particularly, for those tumors located at lower thorax.

Acknowledgements

Not applicable.
The present study was approved by the Ethics Committee of our institute and individual consent for the study was waived.
Not applicable.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Shimizu Y, Kato M, Yamamoto J, et al. EMR combined with chemoradiotherapy: a novel treatment for superficial esophageal squamous-cell carcinoma. Gastrointest Endosc. 2004;59:199–204.CrossRef Shimizu Y, Kato M, Yamamoto J, et al. EMR combined with chemoradiotherapy: a novel treatment for superficial esophageal squamous-cell carcinoma. Gastrointest Endosc. 2004;59:199–204.CrossRef
2.
Zurück zum Zitat Rice TW, Ishwaran H, Hofstetter WL, et al. Recommendations for pathologic staging (pTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. Dis Esophagus. 2016;29:897–905.CrossRef Rice TW, Ishwaran H, Hofstetter WL, et al. Recommendations for pathologic staging (pTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. Dis Esophagus. 2016;29:897–905.CrossRef
3.
Zurück zum Zitat Araki K, Ohno S, Egashira A, et al. Pathologic features of superficial esophageal squamous cell carcinoma with lymph node and distal metastasis. Cancer. 2002;94:570–5.CrossRef Araki K, Ohno S, Egashira A, et al. Pathologic features of superficial esophageal squamous cell carcinoma with lymph node and distal metastasis. Cancer. 2002;94:570–5.CrossRef
4.
Zurück zum Zitat Zhou Y, Du J, Li H, et al. Clinicopathologic analysis of lymph node status in superficial esophageal squamous carcinoma. World J Surg Oncol. 2016;14:259.CrossRef Zhou Y, Du J, Li H, et al. Clinicopathologic analysis of lymph node status in superficial esophageal squamous carcinoma. World J Surg Oncol. 2016;14:259.CrossRef
5.
Zurück zum Zitat Li B, Chen H, Xiang J, et al. Prevalence of lymph node metastases in superficial esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2013;146:1198–203.CrossRef Li B, Chen H, Xiang J, et al. Prevalence of lymph node metastases in superficial esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2013;146:1198–203.CrossRef
6.
Zurück zum Zitat Davison JM, Landau MS, Luketich JD, et al. A model based on pathologic features of superficial esophageal adenocarcinoma complements clinical node staging in determining risk of metastasis to lymph nodes. Clin Gastroenterol Hepatol. 2016;14:369–77 e363.CrossRef Davison JM, Landau MS, Luketich JD, et al. A model based on pathologic features of superficial esophageal adenocarcinoma complements clinical node staging in determining risk of metastasis to lymph nodes. Clin Gastroenterol Hepatol. 2016;14:369–77 e363.CrossRef
7.
Zurück zum Zitat Wang S, Chen X, Fan J, Lu L. Prognostic significance of Lymphovascular invasion for thoracic esophageal squamous cell carcinoma. Ann Surg Oncol. 2016;23:4101–9.CrossRef Wang S, Chen X, Fan J, Lu L. Prognostic significance of Lymphovascular invasion for thoracic esophageal squamous cell carcinoma. Ann Surg Oncol. 2016;23:4101–9.CrossRef
8.
Zurück zum Zitat Endo M, Yoshino K, Kawano T, et al. Clinicopathologic analysis of lymph node metastasis in surgically resected superficial cancer of the thoracic esophagus. Dis Esophagus. 2000;13:125–9.CrossRef Endo M, Yoshino K, Kawano T, et al. Clinicopathologic analysis of lymph node metastasis in surgically resected superficial cancer of the thoracic esophagus. Dis Esophagus. 2000;13:125–9.CrossRef
9.
Zurück zum Zitat Liu L, Hofstetter WL, Rashid A, et al. Significance of the depth of tumor invasion and lymph node metastasis in superficially invasive (T1) esophageal adenocarcinoma. Am J Surg Pathol. 2005;29:1079–85.PubMed Liu L, Hofstetter WL, Rashid A, et al. Significance of the depth of tumor invasion and lymph node metastasis in superficially invasive (T1) esophageal adenocarcinoma. Am J Surg Pathol. 2005;29:1079–85.PubMed
10.
Zurück zum Zitat Leers JM, DeMeester SR, Oezcelik A, et al. The prevalence of lymph node metastases in patients with T1 esophageal adenocarcinoma a retrospective review of esophagectomy specimens. Ann Surg. 2011;253:271–8.CrossRef Leers JM, DeMeester SR, Oezcelik A, et al. The prevalence of lymph node metastases in patients with T1 esophageal adenocarcinoma a retrospective review of esophagectomy specimens. Ann Surg. 2011;253:271–8.CrossRef
11.
Zurück zum Zitat Eguchi T, Nakanishi Y, Shimoda T, et al. Histopathological criteria for additional treatment after endoscopic mucosal resection for esophageal cancer: analysis of 464 surgically resected cases. Mod Pathol. 2006;19:475–80.CrossRef Eguchi T, Nakanishi Y, Shimoda T, et al. Histopathological criteria for additional treatment after endoscopic mucosal resection for esophageal cancer: analysis of 464 surgically resected cases. Mod Pathol. 2006;19:475–80.CrossRef
12.
Zurück zum Zitat Higuchi K, Tanabe S, Koizumi W, et al. Expansion of the indications for endoscopic mucosal resection in patients with superficial esophageal carcinoma. Endoscopy. 2007;39:36–40.CrossRef Higuchi K, Tanabe S, Koizumi W, et al. Expansion of the indications for endoscopic mucosal resection in patients with superficial esophageal carcinoma. Endoscopy. 2007;39:36–40.CrossRef
13.
Zurück zum Zitat Ancona E, Rampado S, Cassaro M, et al. Prediction of lymph node status in superficial esophageal carcinoma. Ann Surg Oncol. 2008;15:3278–88.CrossRef Ancona E, Rampado S, Cassaro M, et al. Prediction of lymph node status in superficial esophageal carcinoma. Ann Surg Oncol. 2008;15:3278–88.CrossRef
14.
Zurück zum Zitat Noguchi H, Naomoto Y, Kondo H, et al. Evaluation of endoscopic mucosal resection for superficial esophageal carcinoma. Surg Laparosc Endosc Percutan Tech. 2000;10:343–50.CrossRef Noguchi H, Naomoto Y, Kondo H, et al. Evaluation of endoscopic mucosal resection for superficial esophageal carcinoma. Surg Laparosc Endosc Percutan Tech. 2000;10:343–50.CrossRef
15.
Zurück zum Zitat Choi JY, Park YS, Jung HY, et al. Feasibility of endoscopic resection in superficial esophageal squamous carcinoma. Gastrointest Endosc. 2011;73:881–9 889 e881–882.CrossRef Choi JY, Park YS, Jung HY, et al. Feasibility of endoscopic resection in superficial esophageal squamous carcinoma. Gastrointest Endosc. 2011;73:881–9 889 e881–882.CrossRef
16.
Zurück zum Zitat Tachibana M, Yoshimura H, Kinugasa S, et al. Clinicopathological features of superficial squamous cell carcinoma of the esophagus. Am J Surg. 1997;174:49–53.CrossRef Tachibana M, Yoshimura H, Kinugasa S, et al. Clinicopathological features of superficial squamous cell carcinoma of the esophagus. Am J Surg. 1997;174:49–53.CrossRef
17.
Zurück zum Zitat Takeuchi H, Kawakubo H, Nakamura R, et al. Clinical significance of sentinel node positivity in patients with superficial esophageal Cancer. World J Surg. 2015;39:2941–7.CrossRef Takeuchi H, Kawakubo H, Nakamura R, et al. Clinical significance of sentinel node positivity in patients with superficial esophageal Cancer. World J Surg. 2015;39:2941–7.CrossRef
18.
Zurück zum Zitat Yuasa Y, Seike J, Yoshida T, et al. Sentinel lymph node biopsy using intraoperative indocyanine green fluorescence imaging navigated with preoperative CT lymphography for superficial esophageal cancer. Ann Surg Oncol. 2012;19:486–93.CrossRef Yuasa Y, Seike J, Yoshida T, et al. Sentinel lymph node biopsy using intraoperative indocyanine green fluorescence imaging navigated with preoperative CT lymphography for superficial esophageal cancer. Ann Surg Oncol. 2012;19:486–93.CrossRef
19.
Zurück zum Zitat Filip B, Scarpa M, Cavallin F, et al. Minimally invasive surgery for esophageal cancer: a review on sentinel node concept. Surg Endosc. 2014;28:1238–49.CrossRef Filip B, Scarpa M, Cavallin F, et al. Minimally invasive surgery for esophageal cancer: a review on sentinel node concept. Surg Endosc. 2014;28:1238–49.CrossRef
20.
Zurück zum Zitat Hayashi H, Tangoku A, Suga K, et al. CT lymphography-navigated sentinel lymph node biopsy in patients with superficial esophageal cancer. Surgery. 2006;139:224–35.CrossRef Hayashi H, Tangoku A, Suga K, et al. CT lymphography-navigated sentinel lymph node biopsy in patients with superficial esophageal cancer. Surgery. 2006;139:224–35.CrossRef
Metadaten
Titel
Lymph node metastatic patterns and its clinical significance for thoracic superficial esophageal squamous cell carcinoma
verfasst von
An Wang
Lu Lu
Jie Fan
Shaohua Wang
Xiaofeng Chen
Publikationsdatum
01.12.2020
Verlag
BioMed Central
Erschienen in
Journal of Cardiothoracic Surgery / Ausgabe 1/2020
Elektronische ISSN: 1749-8090
DOI
https://doi.org/10.1186/s13019-020-01302-z

Weitere Artikel der Ausgabe 1/2020

Journal of Cardiothoracic Surgery 1/2020 Zur Ausgabe

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.